Controlled drug release for inflammatory bowel disease (IBD).

Giridharan Bupesh

doi:10.6026/97320630016513

Abstract

Controlled drug release in formulation is an important area of research. Formulations using crospovidone as super-disintegrants to achieve immediate release once it reaches the ileo- cecal region is relevant. The Eudragit L30D pH dependent polymer that allows drug release after a lag time of 4-5 hrs to achieve desired drug release from the drug delivery system is critical. Hence, pre-formulation to study drug-polymer interaction is essential. The linear correlation between the predicted and actual values for all the batches of optimization is shown with high correlation coefficient (r-value). Therefore, the designed formulation is promising for ileo-cecal targeted pulsatile drug delivery system in the management of Crohn's disease.

Highlights

Inflammatory bowel disease (IBD) is a group of inflammatory conditions of the digestive system [1]
The melting point of budesonide was determined by using capillary method and was found to be 241-245°C (Standard 245255°C) which complies with the reported value
The IR spectra showed no evidence of the chemical interaction between the Budesonide and excipients like, crospovidone, PVP K30, and Eudragit L30D polymers (Figure 1)

Summary

Introduction

Inflammatory bowel disease (IBD) is a group of inflammatory conditions of the digestive system [1]. Available drugs for the treatment of IBD include anti-inflammatory agents such as mesalazine, corticosteroids (prednisolone, methyl prednisolone and budesonide), immunosuppressive agents (azathioprine and cyclosporine), antibiotics (ciprofloxacin, metronidazole) and monoclonal antibodies (Infliximab) to reduce mucosal inflammation [2, 3]. While these treatments are effective and gives symptomatic relief to the patients with innumerable side effects [4]. Interest on targeted delivery system for the treatment of Ulcerative colitis (UC), Crohn’s disease This requires the local delivery of drugs with minimal side effects. It is of interest to develop colon-targeted delivery of budesonide coated with pH sensitive polymer to improve the delivery of drug at the site of action [8]

Results

Discussion

Conclusion